An exploratory study to identify biomarkers of resistance to chemotherapy in multiple myeloma
Not Applicable
- Conditions
- Multiple Myeloma
- Registration Number
- JPRN-UMIN000031866
- Lead Sponsor
- The Institute of Medical Science, The University of Tokyo
- Brief Summary
Results: We identified several driver mutations by combined analysis of next-generation sequencing and existing databases of candidate oncogenes. Furthermore, relapse was detected more sensitively by monitoring the circulating cfDNA with these driver mutations than by conventional serum free-light chain examination. Conclusion: These results suggest the potential utility of cfDNA in the PB plasma of patients as a relevant early biomarker for MM relapse.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are found to be inappropriate for this trial as judged by the principal investigator or the sub-investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method